Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Pharvaris GmbH is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This specific matter is being processed through 1 distinct art unit, which is common for specialized pharmaceutical filings. The prosecution involves a distinct examiner, ensuring a singular point of contact for the current patent application. This focused approach reflects the company's targeted efforts in the Biotechnology & Pharmaceuticals sector.
ROZOF, TIMOTHY R is the busiest examiner for the Pharvaris GmbH portfolio, currently overseeing the pending office action. Because there is only a single pending office action in total, this examiner handles the entirety of the company's active prosecution workload. The alignment of the art unit and the examiner suggests a singular administrative path for this case. Practitioners should note that the active filing represents the full scope of the current data for this entity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18850703 | THERAPEUTIC USES OF BRADYKININ B2-RECEPTOR ANTAGONISTS | ROZOF, TIMOTHY R | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18850703 | THERAPEUTIC USES OF BRADYKININ B2-RECEPTOR ANTAGONISTS | ROZOF, TIMOTHY R | 1629 | §102§112DP | Non-Final OA | — | Pending | Sep 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial